RxDoctor Payments Data

Timothy Gray, DO

Family Medicine · Forest Grove, ORNPI 1699770057

Payments from drug & device makers

$1,015in general payments, 2019–2025

Across 69 payments — averaging $14.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$303
  • Johnson & Johnson$215
  • Amarin Pharma, Inc.$96
  • Amgen$79
  • AbbVie$60
  • Exact Sciences$60
  • plus $201 from 9 others

What the payments were for

  • Food & beverage$1,015100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,015 in reported general payments places this provider in the 85th percentile of 1,221 family medicine providers in Oregon.

See all family medicine providers in Oregon

Medicare billing

Part B allowed, 2024
$50,260
Medicare patients
235
Services billed
876

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide27$49,737
JardianceEmpagliflozin43$43,462
EliquisApixaban34$38,152
XareltoRivaroxaban32$34,178
MyrbetriqMirabegron12$10,419
Breo ElliptaFluticasone/Vilanterol17$9,074
SymbicortBudesonide/Formoterol Fumarate19$8,064
ShingrixVaricella-Zoster Ge/As01b/Pf34$7,453
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$7,091
Lantus SolostarInsulin Glargine,hum.Rec.Anlog63$5,747
Atorvastatin Calcium496$5,569
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$5,565
ArexvyRsvpref3 Antigen/As01e/Pf15$4,796
Tresiba Flextouch U-100Insulin Degludec12$4,766
Omeprazole235$4,260

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$20$49,73727 claims
Boehringer IngelheimJardiance$12$43,46243 claims
Johnson & JohnsonXarelto$215$34,17832 claims
GSKBreo Ellipta, Shingrix, Arexvy$38$21,32466 claims
Astellas Pharma US IncMyrbetriq$21$10,41912 claims
AstraZenecaSymbicort$303$8,06419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,221 family medicine providers in Oregon.

Other family medicine in Forest Grove

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →